These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 8368734)

  • 21. Association of HLA phenotype with response to active specific immunotherapy of melanoma.
    Mitchell MS; Harel W; Groshen S
    J Clin Oncol; 1992 Jul; 10(7):1158-64. PubMed ID: 1607920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
    Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
    Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.
    Mukherji B; Guha A; Chakraborty NG; Sivanandham M; Nashed AL; Sporn JR; Ergin MT
    J Exp Med; 1989 Jun; 169(6):1961-76. PubMed ID: 2471770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in surface phenotype and mechanism of action between alloantigen-specific CD8+ cytotoxic and suppressor T cell clones.
    Koide J; Engleman EG
    J Immunol; 1990 Jan; 144(1):32-40. PubMed ID: 1967266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
    Darrow TL; Slingluff CL; Seigler HF
    J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.
    Crowley NJ; Slingluff CL; Darrow TL; Seigler HF
    Cancer Res; 1990 Feb; 50(3):492-8. PubMed ID: 2404572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
    Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
    Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
    Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
    Kawakami Y; Zakut R; Topalian SL; Stötter H; Rosenberg SA
    J Immunol; 1992 Jan; 148(2):638-43. PubMed ID: 1729379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells.
    Zennadi R; Abdel-Wahab Z; Seigler HF; Darrow TL
    Cell Immunol; 2001 Jun; 210(2):96-105. PubMed ID: 11520076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.
    Osanto S; Schiphorst PP; Weijl NI; Dijkstra N; Van Wees A; Brouwenstein N; Vaessen N; Van Krieken JH; Hermans J; Cleton FJ; Schrier PI
    Hum Gene Ther; 2000 Mar; 11(5):739-50. PubMed ID: 10757353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro.
    Imro MA; Dellabona P; Manici S; Heltai S; Consogno G; Bellone M; Rugarli C; Protti MP
    Hum Gene Ther; 1998 Jun; 9(9):1335-44. PubMed ID: 9650618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
    Abdel-Wahab ZA; Osanto S; Darrow TL; Barber JR; Vervaert CE; Gangavalli R; McCallister TJ; Seigler HF
    Cancer Gene Ther; 1994 Sep; 1(3):171-9. PubMed ID: 7621248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
    Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G
    J Exp Med; 1993 Apr; 177(4):989-98. PubMed ID: 8459226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.
    Hayashi Y; Hoon DS; Foshag LJ; Park MS; Terasaki PI; Morton DL
    Cancer; 1993 Aug; 72(3):750-9. PubMed ID: 8334627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.